查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048362

制酸劑市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用途、地區和競爭格局分類，2021-2031年

Antacids Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Tablet, Liquid, others), By End-use (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球制酸劑市場預計將從 2025 年的 72.1 億美元成長到 2031 年的 91.3 億美元，複合年成長率為 4.01%。

制酸劑是一種旨在中和胃酸的藥物，可以緩解灼熱、胃酸倒流和消化不良等症狀。這個市場成長的主要原因是胃腸道疾病的增加，而這些疾病通常與久坐的生活方式和不健康的飲食習慣有關，此外，老年人口的成長也使得老年人更容易出現消化器官系統問題。另外，非處方藥（OTC）的廣泛普及，使得人們無需就醫即可輕鬆獲得治療輕微健康問題的藥物，這也是成長要素的主要因素。英國藥品協會2024年的數據顯示，89%的成年人對使用非處方藥來控制症狀充滿信心，凸顯了自我護理在推動市場需求方面的重要角色。

市場概覽
預測期 2027-2031
市場規模：2025年 72.1億美元
市場規模：2031年 91.3億美元
複合年成長率：2026-2031年 4.01%
成長最快的細分市場 藥片
最大的市場 北美洲

然而，全球制酸劑市場擴張面臨的主要障礙是公眾對長期服用制酸劑潛在副作用（例如腎損傷和電解質失衡）的認知不斷提高。這些安全隱患導致監管審查力度加大，並可能促使消費者考慮其他治療方法或改變生活方式。因此，傳統制酸劑產品的長期成長前景可能受到限制。

市場促進因素

胃食道逆流 (GERD) 的日益普及是全球制酸劑市場的主要驅動力，這與久坐不動的生活方式和不健康的飲食習慣密切相關。隨著酸相關疾病的日益普遍，人們對使用酸中和劑即時緩解症狀的需求激增，促使生產者擴大生產。根據美國國立衛生研究院 (NIH) 2024 年 11 月發表的題為《全球胃食道逆流症負擔與趨勢》的報導，全球約有 8.256 億胃食道逆流症患者。這一重要的公共衛生趨勢保證了對制酸劑的持續需求。不斷擴大的患者群體，尤其受到人口老化和肥胖率上升的影響，需要持續治療，從而確保了該市場的長期收入成長。

同時，消費者日益成長的自我治療傾向也顯著推動了市場擴張。越來越多的人選擇購買易於取得的非處方藥（OTC）來消化器官系統問題，而無需專業醫療建議。這一趨勢得益於知名品牌的廣泛普及和便利的線上購物平台，使消費者能夠獨立應對輕微症狀。 Haleon於2024年10月發布的2024年第三季財報顯示，其消化健康業務部門的有機銷售額成長了5.9%，主要得益於Tums品牌兩位數的成長，進一步印證了消費者健康自我管理的趨勢。此外，賽諾菲消費者保健業務部門在2024年第二季（截至7月）的銷售額成長了9.6%，也進一步印證了這個產業發展勢頭，凸顯了消化器官系統健康領域的強勁表現。

市場挑戰

人們越來越意識到長期服用制酸劑的潛在副作用，尤其是腎臟併發症和電解質失衡，這成為全球市場面臨的主要障礙。隨著消費者健康意識的增強，以及長期服用制酸劑與腎臟負擔之間聯繫的日益清晰，人們對常規和預防性使用這些產品的抵觸情緒也越來越高。這種日益嚴格的審查正在改變人們對制酸劑的看法，使其從“無害的日常用品”轉變為“需要謹慎使用的藥物”，導致消費者減少購買頻率，或轉而改變生活方式或尋求醫生處方的替代療法，最終導致經常性收入下降。

由於消費者在面臨潛在安全風險時對自我管理健康問題的信心下降，市場成長放緩的情況進一步加劇。英國藥品協會發布的2025年報告顯示，成年人首次就可自行治療的症狀諮詢藥劑師的比例將下降至51%，顯示人們對非處方藥的依賴程度將顯著降低。這一趨勢表明，對健康併發症的擔憂正促使相當一部分市場從非處方藥轉向醫療專業人員，阻礙了傳統制酸劑行業的銷售成長。

市場趨勢

軟糖和軟咀嚼片等創新劑型的出現正在改變全球制酸劑市場的消費者購買模式。這是因為越來越多的使用者更注重感官體驗和使用便利性，而非傳統的粉末片劑。製造商正積極拓展產品線，推出類似糖果甜點的非藥物產品，以提高患者的用藥依從性，並吸引那些將消化健康視為生活方式重要組成部分的年輕消費者。這種策略有效地維持了整個品類的價值。根據Haleon於2025年10月發布的2025年第三季財報，消化健康領域的有機銷售額成長了2.1%，這主要得益於「TUMS Gummy Bites Plus」等創新產品的成功。這一趨勢迫使競爭對手加大投入，改善產品的口味和質地，以在競爭激烈的零售市場中脫穎而出。

同時，在「潔淨標示」運動的推動下，以及消費者對合成化學品長期安全性的日益擔憂，市場對草本和植物來源制酸劑劑的需求不斷成長。這一趨勢正將薄荷和洋甘菊等植物成分從特殊療法提升為廣泛接受的治療選擇，大型製藥公司也紛紛收購和開發天然產品線，以維繫其注重健康的客戶群。這種轉變所帶來的財務影響顯而易見。根據拜耳公司於2025年11月發布的2025年第三季財報，經外匯和產品組合調整後，其胃腸道健康業務的銷售額成長了6.5%，這主要得益於其草本品牌Iberogast的強勁表現。因此，市場呈現兩極化，天然配方在高價位區間獲得支持，同時也對傳統質子幫浦阻斷劑的主導地位構成挑戰。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球制酸劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（片劑、液體、其他）
    • 透過申請（零售藥局、醫院藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美制酸劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲制酸劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區制酸劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲制酸劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲制酸劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球制酸劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GlaxoSmithKline plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Sanofi SA
  • Reckitt Benckiser Group plc
  • Sun Pharmaceuticals Ltd.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Procter & Gamble Co.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20726

The global antacids market is projected to expand from USD 7.21 billion in 2025 to USD 9.13 billion by 2031, achieving a compound annual growth rate of 4.01%. Antacids are pharmaceutical products designed to neutralize stomach acid, offering relief from symptoms like heartburn, acid reflux, and indigestion. This market's growth is primarily driven by the increasing occurrence of gastrointestinal issues, often linked to sedentary habits and unhealthy diets, combined with a rising elderly population more susceptible to digestive problems. Moreover, the market gains significantly from consumers' widespread use of readily available over-the-counter treatments for minor health issues, bypassing the need for a doctor. Data from the Proprietary Association of Great Britain in 2024 showed that 89% of adults were confident in using nonprescription medicines for symptom management, highlighting the crucial role of self-care in boosting market demand.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.21 Billion
Market Size 2031USD 9.13 Billion
CAGR 2026-20314.01%
Fastest Growing SegmentTablet
Largest MarketNorth America

However, a key obstacle to the global antacids market's expansion is the increasing public awareness of potential negative side effects associated with long-term use, such as kidney problems and electrolyte imbalances. These safety concerns have intensified regulatory oversight and may encourage consumers to explore other treatments or lifestyle changes, thus potentially limiting the long-term growth prospects of conventional antacid products.

Market Driver

The rising prevalence of Gastroesophageal Reflux Disease (GERD) is a core driver for the global antacids market, closely linked to the increase in sedentary lifestyles and poor dietary habits. As acid-related conditions become more common, the need for immediate symptom relief from acid-neutralizing medications has soared, prompting manufacturers to boost production. A November 2024 article from the National Institutes of Health, "Global burden and temporal trends in GERD," reported approximately 825.6 million prevalent GERD cases globally. This significant public health trend ensures ongoing demand for antacid medications. This expanding patient demographic, largely influenced by an aging population and rising obesity rates, requires continuous treatment, thereby securing the market's long-term revenue growth.

Simultaneously, a growing consumer preference for self-medication is substantially fueling market expansion, with individuals increasingly choosing readily available over-the-counter (OTC) treatments for digestive issues without needing professional medical advice. This trend is bolstered by the broad availability of established brands and convenient digital shopping platforms, enabling consumers to manage minor symptoms independently. Haleon's Q3 2024 Trading Statement, from October 2024, noted a 5.9% organic revenue increase in its Digestive Health division, largely due to double-digit growth in the Tums brand, confirming this move towards self-directed health management. Further supporting this industry momentum, Sanofi's Consumer Healthcare unit reported a 9.6% sales growth in the second quarter of July 2024, underscoring the strong financial performance of the digestive wellness sector.

Market Challenge

Increasing awareness regarding the potential adverse effects of prolonged antacid consumption, notably renal complications and electrolyte imbalances, presents a significant hurdle for the global market. As consumers become more informed about health, the link between ongoing antacid use and kidney stress discourages the routine, preventive use of these products. This heightened scrutiny shifts the perception of antacids from a harmless daily item to a medication requiring careful consideration, leading users to buy them less often or switch to lifestyle adjustments and doctor-prescribed alternatives, consequently diminishing recurring revenue.

This market slowdown is exacerbated by declining consumer confidence in self-managing health issues when faced with potential safety risks. A 2025 report from the Proprietary Association of Great Britain showed that the percentage of adults first consulting pharmacists for self-treatable conditions dropped to 51%, indicating a notable decrease in reliance on nonprescription options. This pattern suggests that concerns about health complications are pushing a considerable segment of the market towards medical professionals instead of over-the-counter remedies, thereby hindering volume growth in the traditional antacid sector.

Market Trends

The emergence of innovative delivery formats, notably gummies and soft chews, is transforming consumer buying patterns in the global antacids market, as users increasingly value sensory experience and ease of use over conventional chalky tablets. Manufacturers are actively expanding their product ranges with non-medicinal options that resemble confectionery, enhancing patient compliance and appealing to younger consumers who see digestive well-being as integral to their lifestyle. This approach has effectively maintained category value; Haleon's Q3 2025 Trading Statement from October 2025 reported a 2.1% organic revenue growth in its Digestive Health division, specifically attributing it to successful product innovations like TUMS Gummy Bites Plus. This development necessitates competitors to invest in improving flavor and texture to distinguish their products in a competitive retail landscape.

Simultaneously, there is an increasing demand for herbal and plant-based antacid alternatives, fueled by the "clean label" movement and growing consumer distrust regarding the long-term safety of synthetic chemicals. This trend has elevated botanical ingredients such as peppermint and chamomile from specialized remedies to widely accepted therapeutic choices, leading major pharmaceutical companies to acquire or develop natural product lines to retain health-conscious clientele. The financial effects of this shift are clear; Bayer's Quarterly Statement Q3 2025 from November 2025 indicated a 6.5% increase in Digestive Health sales on a currency- and portfolio-adjusted basis, significantly boosted by the strong performance of the herbal brand Iberogast. As a result, the market is observing a divide where natural formulations attract higher prices while posing a challenge to the established dominance of traditional proton pump inhibitors.

Key Market Players

  • GlaxoSmithKline plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Sanofi SA
  • Reckitt Benckiser Group plc
  • Sun Pharmaceuticals Ltd.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Procter & Gamble Co.

Report Scope

In this report, the Global Antacids Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antacids Market, By Type

  • Tablet
  • Liquid
  • others

Antacids Market, By End-use

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

Antacids Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antacids Market.

Available Customizations:

Global Antacids Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antacids Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Tablet, Liquid, others)
    • 5.2.2. By End-use (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Antacids Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End-use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antacids Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End-use
    • 6.3.2. Canada Antacids Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End-use
    • 6.3.3. Mexico Antacids Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End-use

7. Europe Antacids Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End-use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antacids Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End-use
    • 7.3.2. France Antacids Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End-use
    • 7.3.3. United Kingdom Antacids Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End-use
    • 7.3.4. Italy Antacids Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End-use
    • 7.3.5. Spain Antacids Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End-use

8. Asia Pacific Antacids Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End-use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Antacids Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End-use
    • 8.3.2. India Antacids Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End-use
    • 8.3.3. Japan Antacids Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End-use
    • 8.3.4. South Korea Antacids Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End-use
    • 8.3.5. Australia Antacids Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End-use

9. Middle East & Africa Antacids Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End-use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Antacids Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End-use
    • 9.3.2. UAE Antacids Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End-use
    • 9.3.3. South Africa Antacids Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End-use

10. South America Antacids Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End-use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Antacids Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End-use
    • 10.3.2. Colombia Antacids Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End-use
    • 10.3.3. Argentina Antacids Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Antacids Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bayer AG
  • 15.3. Boehringer Ingelheim International GmbH
  • 15.4. Dr. Reddy's Laboratories Ltd.
  • 15.5. Sanofi SA
  • 15.6. Reckitt Benckiser Group plc
  • 15.7. Sun Pharmaceuticals Ltd.
  • 15.8. Takeda Pharmaceutical Company Limited
  • 15.9. Pfizer Inc.
  • 15.10. Procter & Gamble Co.

16. Strategic Recommendations

17. About Us & Disclaimer